The share price of Cambridge-based pharmaceutical company AstraZeneca rose in European trading on Monday after the company reconfirmed its full-year outlook following second-quarter results that beat analyst expectations. Net profit climbed more than 2% to $2.51 billion (€2.2bn) in the three months to the end of June compared with the same period last year, driven by continued strong growth in sales of its cancer medicines. AstraZeneca said total revenue increased 5% at constant exchange rates to $15.38bn (€13.49bn) in the quarter, driven by growth in cancer and rare disease medicines. Reflecting strong underlying profitability, the company reported core earnings per share of $2.63, up 18% at constant exchange rates, which beat analysts' forecast of $2.48. This follows a slump in early July after its drug Wainua failed to meet targets, in a rare setback for the drugmaker.